Related Experiment Video
Updated: Sep 28, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice
Lucas Opazo-Ríos1,2, Antonio Tejera-Muñoz3, Manuel Soto Catalan1
1Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Universidad Autónoma de Madrid, Madrid, Spain.
Abstract:
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high residual risk of disease progression to end-stage renal failure. To further understand the pathogenesis of tissue injury in this disease, by means of the Next-Generation Sequencing, we have studied the microRNA (miRNA) differential expression pattern in kidneys of Black and Tan Brachyury (BTBR) ob/ob (leptin deficiency mutation) mouse. This experimental model of type 2 diabetes and obesity recapitulates the key histopathological features described in advanced human DN and therefore can provide potential useful translational information. The miRNA-seq analysis, performed in the renal cortex of 22-week-old BTBR ob/ob mice, pointed out a set of 99 miRNAs significantly increased compared to non-diabetic, non-obese control mice of the same age, whereas no miRNAs were significantly decreased. Among them, miR-802, miR-34a, miR-132, miR-101a, and mir-379 were the most upregulated ones in diabetic kidneys. The in silico prediction of potential targets for the 99 miRNAs highlighted inflammatory and immune processes, as the most relevant pathways, emphasizing the importance of inflammation in the pathogenesis of kidney damage associated to diabetes. Other identified top canonical pathways were adipogenesis (related with ectopic fatty accumulation), necroptosis (an inflammatory and regulated form of cell death), and epithelial-to-mesenchymal transition, the latter supporting the importance of tubular cell phenotype changes in the pathogenesis of DN. These findings could facilitate a better understanding of this complex disease and potentially open new avenues for the design of novel therapeutic approaches to DN.
Insights
Diabetic nephropathy (DN) involves increased microRNAs (miRNAs) in mouse kidneys, particularly those linked to inflammation and cell death. This study identifies key miRNAs and pathways, offering insights into DN pathogenesis and potential new therapies.
Area of Science:
- Nephrology
- Molecular Biology
- Genomics
Background:
- Diabetic nephropathy (DN) is a leading cause of chronic kidney disease globally.
- Despite advances, a significant risk of progression to end-stage renal failure remains.
- Understanding DN pathogenesis is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate microRNA (miRNA) differential expression in the kidneys of a mouse model of type 2 diabetes and obesity.
- To identify specific miRNAs and pathways involved in the pathogenesis of diabetic kidney injury.
Main Methods:
- Utilized Next-Generation Sequencing (miRNA-seq) to analyze miRNA expression patterns.
- Employed an experimental model: Black and Tan Brachyury (BTBR) ob/ob mice, mimicking human DN.
- Performed in silico prediction of potential miRNA targets and associated biological pathways.
Main Results:
- Identified 99 significantly upregulated miRNAs in the kidneys of diabetic mice compared to controls.
- Key upregulated miRNAs included miR-802, miR-34a, miR-132, miR-101a, and miR-379.
- In silico analysis highlighted inflammation, immune processes, adipogenesis, necroptosis, and epithelial-to-mesenchymal transition as critical pathways.
Conclusions:
- MicroRNA dysregulation, particularly upregulation, plays a significant role in diabetic nephropathy pathogenesis.
- Inflammation and immune responses are central to kidney damage in diabetes.
- Findings provide a foundation for understanding DN and developing targeted therapies.

